Breaking barriers in gene delivery through AI
Artemis is Avista’s powerful AI platform for capsid design
Artemis is powered by AI models that leverage Avista’s high-quality in vivo datasets, protein language models and molecular dynamics of AAV capsids to push beyond what was previously possible in capsid design. Our approach, built on a foundation of high-resolution data, structural insights into capsid biology and machine learning, rapidly explores an expanding design space to develop completely novel AAV capsids with new functionalities that were once out of reach.
Gold standard data
Avista has generated large, high-quality, curated in-vivo datasets of AAV variants with single-cell resolution, providing detailed information on cell type, tissue tropism and route of administration —key knowledge to ensure that our capsids are efficiently getting to the right place for clinical success.
Structural dynamics
Avista is pioneering the design of AAVs using guidance from biophysical and mechanistic information obtained from molecular dynamics simulations of thousands of AAV capsids. Artemis extends protein sequence models with models of structural mechanism underlying capsid fitness that sequence alone can not capture.
Powerful AI models
Avista’s Artemis AI platform integrates our gold standard data with proprietary protein language models and molecular dynamics to create advanced models for capsid design. Artemis not only generates novel best-in-class vectors, but also provides structural and mechanistic insights into their biology.
The combination of sequence and structural mechanism models uniquely position Avista as a leader in capsid design, with the ability to rapidly develop safe and highly efficient capsids for effective gene therapies in tissues across the body.
Avista capsids
Our capsids are optimized for safe, clinically-relevant delivery routes and validated across species to support successful translation to human patients.
Retina
ATX002
Optimized for intravitreal delivery, producing strong pan-retinal expression across all regions of the retina, including fovea and periphery. 14x increase in cells transduced compared to clinical-stage 7m8. 24x increase in cells transduced compared to AAV2.
ATX027
Optimized for intravitreal delivery, resulting in robust pan-retinal expression across all regions of the retina, including fovea and periphery. 19x increase in cells transduced compared to clinical-stage 7m8. 33x increase in cells transduced compared to AAV2.
Brain
ATX001
Local delivery results in robust distribution throughout the brain from ICM and ICV injection, with specific targeting of neurons.
